Suppr超能文献

皮肤T细胞淋巴瘤中与组蛋白去乙酰化酶抑制剂相关的可变剪接的全基因组鉴定。

Genome-wide identification of alternative splicing associated with histone deacetylase inhibitor in cutaneous T-cell lymphomas.

作者信息

Yu Shirong, Zhang Jingzhan, Ding Yuan, Kang Xiaojing, Pu Xiongming

机构信息

Xinjiang Medical University, Urumqi, China.

Department of Dermatology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China.

出版信息

Front Genet. 2022 Sep 6;13:937623. doi: 10.3389/fgene.2022.937623. eCollection 2022.

Abstract

Cutaneous T-cell lymphomas (CTCLs) are a kind of non-Hodgkin lymphoma that originates from skin, which is difficult to treat with traditional drugs. Human histone deacetylase inhibitors (HDACi) targeted therapy has become a promising treatment strategy in recent years, but some patients can develop resistance to the drug, leading to treatment failure. There are no public reports on whether alternative splicing (AS) and RNA binding proteins (RBP) affect the efficacy of targeted therapy. Using data from the Gene Expression Omnibus (GEO) database, we established a co-change network of AS events and RBP in CTCLs for the first time, and analyzed the potential regulatory effects of RBP on HDACi-related AS events. The dataset GSE132053, which contained the RNA sequence data for 17 HDACi samples, was downloaded and clean reads were aligned to the human GRCh38 genome by hierarchical indexing for spliced alignment of the transcripts, allowing four mismatches. Gene expression levels were evaluated using exons per million fragments mapped for each gene. Student's t-tests were performed to evaluate the significance of changes in ratios for AS events, and regulated alternative splicing events (RASEs) were defined as events with values less than 0.05. To sort the differentially expressed genes functional categories, Gene Ontology terms and Kyoto Encyclopedia of Genes and Genomes pathways were identified using the KOBAS 2.0 server. The regulatory mechanisms of the RASEs and RBPs were evaluated using Pearson's correlation coefficient. Seven indirect events of HDACi resistance or sensitivity were identified: NIR_5151_RP11-977G19.10, NIR_4557_IRAG2, NIR_11870_SUMO1, NIR_5347_ING4, NIR_17935_DNAJC2, NIR_17974_CBLL1, and NIR_422_SLC50A1. The potential regulatory relationships between RBPs and HDACi-sensitive RASEs were also analyzed. and significantly affected NIR_11870_SUMO1, suggesting a potential regulatory relationship. Additionally, may regulate NIR_5347_ING4, may regulate NIR_17935_DNAJC2, and and may regulate NIR_422_SLC5A1. Overall, our findings establish a theoretical foundation for the precise targeted treatment of CTCLs with HDACi.

摘要

皮肤T细胞淋巴瘤(CTCLs)是一种起源于皮肤的非霍奇金淋巴瘤,传统药物难以对其进行治疗。近年来,人类组蛋白去乙酰化酶抑制剂(HDACi)靶向治疗已成为一种有前景的治疗策略,但一些患者可能会对该药物产生耐药性,导致治疗失败。关于可变剪接(AS)和RNA结合蛋白(RBP)是否影响靶向治疗疗效尚无公开报道。我们首次利用基因表达综合数据库(GEO)的数据,建立了CTCLs中AS事件和RBP的共变网络,并分析了RBP对HDACi相关AS事件的潜在调控作用。下载了包含17个HDACi样本RNA序列数据的数据集GSE132053,并通过转录本剪接比对的分层索引将clean reads与人类GRCh38基因组进行比对,允许四个错配。使用每个基因每百万映射片段的外显子来评估基因表达水平。进行学生t检验以评估AS事件比值变化的显著性,将调控可变剪接事件(RASEs)定义为比值小于0.05的事件。为了对差异表达基因的功能类别进行分类,使用KOBAS 2.0服务器鉴定基因本体论术语和京都基因与基因组百科全书通路。使用皮尔逊相关系数评估RASEs和RBPs的调控机制。鉴定出7个HDACi耐药或敏感的间接事件:NIR_5151_RP11-977G19.10、NIR_4557_IRAG2、NIR_11870_SUMO1、NIR_5347_ING4、NIR_17935_DNAJC2、NIR_17974_CBLL1和NIR_422_SLC50A1。还分析了RBPs与HDACi敏感RASEs之间的潜在调控关系。 和 显著影响NIR_11870_SUMO1,提示存在潜在调控关系。此外, 可能调控NIR_5347_ING4, 可能调控NIR_17935_DNAJC2, 和 可能调控NIR_422_SLC5A1。总体而言,我们的研究结果为HDACi精准靶向治疗CTCLs奠定了理论基础。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/24a3/9485882/a3afa639fc69/fgene-13-937623-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验